麻豆传媒

ROME -- Antithrombotic medications successfully treated plaque erosion without stenting in a proof-of-concept study reported here.

With 1 month of antithrombotic therapy after finding plaque erosion on optical coherence tomography (OCT), patients' median thrombus volume plummeted from 3.7 mm³ to 0.2 mm³ (P<0.001). In addition, minimal flow area rose from 1.7 mm² to 2.1 mm² (P=0.002), according to , of Boston's Massachusetts General Hospital.

Minimum lumen diameter increased from 1.35 mm to 1.54 mm (P<0.001). In addition, 78.3% of patients had their thrombus volume slashed in half or more; another 36.7% had no residual thrombus on follow-up.

Jang presented the results of the so-called EROSION study at the annual meeting of the European Society of Cardiology; they were also published simultaneously in the .

"Randomized trials will be needed to reproduce this pilot data and to further evaluate the long-term outcome of this new treatment strategy in patients with acute coronary syndrome [ACS] caused by plaque erosion," Jang said.

However, the minimum lumen diameter achieved after therapy (1.54 mm) was theoretically still flow-limiting in a non-infarcted area, session discussant , of Erasmus University in Rotterdam, The Netherlands, pointed out.

What's more, he added, 66% of patients did not have their minimum lumen area rise above 1.95 mm², a threshold for positive fractional flow reserve.

EROSION included 60 patients (out of 405 screened) who presented with an ACS at the emergency department of a single center in China and had plaque erosion identified on OCT without plaque rupture or major stenosis. Those with the lowest left ventricular ejection fractions (less than 30%) were excluded, as well as those who could not tolerate the antithrombotics.

One patient died of gastrointestinal bleeding; another had target lesion revascularization following no angiographic improvement with the antithrombotics.

Before invasive imaging, patients got aspirin 300 mg, ticagrelor 180 mg, and unfractionated heparin 100 IU/kg. The antithrombotics continued after catheterization, including dual antiplatelet therapy with aspirin and ticagrelor thereafter.

Most patients (83.6%) also received manual aspiration thrombectomy as part of their treatment.

Serruys noted the use of the glycoprotein IIb/IIIa inhibitor tirofiban (Aggrastat) in two-thirds of participants involved -- another limitation of Jang's non-randomized, unblinded trial.